Back

ENTRIGUE: Pegozafermin for the treatment of severe hypertriglyceridemia.

26 August 2022 (12:00 - 12:15)
Organised by:
Congress Presentation Part of: Late-Breaking Science - Innovations in drug treatment Drug therapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Deepak Bhatt

Icahn School of Medicine at Mount Sinai, New York City (United States of America)

3 More presentations in this session

Presentation thumbnail
Mechanisms of the clinical benefits of SGLT2i in heart failure (EMPEROR-Pooled)
Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)
Slides Video
Presentation thumbnail
Lifetime prediction and Treatment Benefit in HFrEF (LIFE-HF).
Doctor S. Koudstaal (Gouda, NL)
Slides Video
Presentation thumbnail
Genotype-Guided Oral P2Y12 Inhibitor Therapy Reduces Cumulative Ischemic Events Following Percutaneous Coronary Intervention - A Prespecified Secondary Analysis of the TAILOR-PCI Randomised Trial
Doctor B. Ingraham (Rochester, US)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Science - Innovations in drug treatment
Video

The Event

Event poster

ESC Congress 2022

26 August 2022 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Pemafibrate has a novel mechanism of action to lower LDL-C and ApoB in patients with higher LDL-C levels: Insights from a phase 2 exploratory clinical pharmacology crossover study
thumbnail
Congress Presentation
Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: the Essence-TIMI 73b trial
thumbnail
Congress Presentation
Update on triglycerides and nutraceuticals

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources